Clinical Trials Browser

OTHER × Smoldering Multiple Myeloma × daratumumab × Clear all

NCT03236428 2025-03-05

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Phase 2 Active not recruiting

Smoldering Multiple Myeloma, Paraproteinemias

NCT03289299 2023-12-12

ASCENT

Phase 2 Active not recruiting

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell